There is a significant body of scientific data that demonstrates the anti-cancer and neurological properties of sulforaphane. Sulforaphane, which is derived from glucoraphanin (a molecule of botanical origin), has substantial evidence of its efficacy (in-vitro and in-vivo) in academic research, with some 800 peer-reviewed scientific publications to date.
Until now, no clinical studies have been able to be performed on pure sulforaphane as it is inherently unstable (it needs to be stored at -20˚C under an inert gas). Evgen holds the rights to a suite of patents and applications on a synthetic stabilised sulforaphane (“Sulforadex®”) that, for the first time, enables the development of a stable pharmaceutical (which can be delivered via a capsule or pill format). Sulforadex completed a First-in-Man clinical trial in March 2013.
Evgen has identified market opportunities associated with Sulforadex as a safe, long-term monotherapy for patients with early stage “indolent” prostate cancer and also as an adjunct to both first-line hormonal therapy for ER+ breast cancer and recurrent breast cancer.